Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials

Mark Nelson, Keikawus Arastéh, Bonaventura Clotet, David A. Cooper, Keith Henry, Christine Katlama, Jacob P. Lalezari, Adriano Lazzarin, Julio S.G. Montaner, Mary O'Hearn, Peter J. Piliero, Jacques Reynes, Benoit Trottier, Sharon L. Walmsley, Calvin Cohen, Joseph J. Eron, Daniel R. Kuritzkes, Joep Lange, Hans Jürgen Stellbrink, Jean François DelfraissyNeil E. Buss, Lucille Donatacci, Cynthia Wat, Lynn Smiley, Martin Wilkinson, Adeline Valentine, Denise Guimaraes, Ralph DeMasi, Jain Chung, Miklos P. Salgo

Research output: Contribution to journal › Article › peer-review

140 Scopus citations

Fingerprint

Dive into the research topics of 'Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials'. Together they form a unique fingerprint.

Medicine & Life Sciences